{"id":"tp-31861","type":"article-newspaper","title":"Ultragenyx Pharmaceutical Inc. Agrees to Sell Fayuvi Voucher for $203 Million","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/31861","datePublished":"2026-10-14T13:55:28.000Z","dateModified":"2026-10-14T13:55:28.000Z","language":"en","abstract":"The priority review voucher was received in connection with Fayuvi’s approval in September. The therapy is also known as rebisufligene etisparvovec.","section":"Business","references":[]}